HyperMed’s latest news

HyperMed Imaging Announces Sales Availability for Its New HyperView Product

October 16, 2017 / Memphis, TN

HyperMed Imaging, Inc. announced today that the company is now offering for sale its new HyperView™ Imaging System to customers in the United States.  Customers are invited to contact the company for more information.  HyperMed will be present at the Symposium on Advanced Wound Care (SAWC) in Las Vegas, NV on October 20 – 22, 2017 where product demonstrations will be available at exhibit booth #443.

The HyperView System is FDA cleared, and it represents a new standard of performance when assessing tissue oxygenation and perfusion in patients with potential circulatory compromise.  The HyperView is a fast, handheld, battery operated, non-invasive and portable diagnostic imaging device that is used to assess tissue oxygenation without contacting the patient and without the need for injectable contrast. The system uses proprietary technology to capture color-coded images containing data that provides the clinician critical information such as oxyhemoglobin levels (Oxy), deoxyhemoglobin levels (Deoxy) and oxygen saturation (O2Sat) in superficial tissue.  Such information may assist clinicians when determining if a patient has adequate blood perfusion to heal a wound or maintain healthy tissue.  Understanding both arterial and venous sufficiency in the surface tissue may enable clinicians to make more informed decisions regarding when to intervene.  The HyperView system also helps document perfusion levels before and after vascular interventional procedures such as: peripheral bypass, stent placement, or balloon angioplasty.

HyperMed’s Vice President of Sales, Annette Plishka, commented, “We are pleased to offer the new HyperView system to our customers in the USA.  There are many important applications for this exciting new diagnostic imaging device in wound care, vascular intervention and reconstructive surgery.”  HyperMed’s President and CEO, Mark Darty added, “Early market feedback from customers has confirmed that HyperView is a game changer.  It is a product poised to impact a number of important market segments.  The low cost, speed, portability, ease of use and high-quality data and imagery provide clinicians a new class of tool to rapidly assess perfusion and locate ischemic tissue.  This information helps caregivers better understand potential circulatory compromise and allow more informed treatment of complications of vascular disease and diabetes.”

HyperMed Imaging, Inc. is a privately owned medical device company located in Memphis, TN.  HyperMed pioneered the use of hyperspectral imaging for assessment of tissue oximetry and HyperMed’s core technology has over 10 years of established clinical efficacy.  With over 50 issued patents and more than 50 additional patents pending worldwide, HyperMed is the market leader in hyperspectral medical imaging.

For more information, visit: https://www.hypermed.com/

HyperMed and HyperView are trademarks of HyperMed Imaging, Inc.

Max Mortensen, PhD
VP Regulatory, Quality and Clinical Affairs
1-844-HYPRMED / 1-844-497-7633

101-D097 Rev. A

HyperMed’s new tissue oximetry device called HyperView™ is FDA 510(k) cleared.
HyperMed, HyperView, OxyVu™-1 and the company logo are trademarks of HyperMed Imaging, Inc.